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Abstract
Background: The aim of this study was to investigate the potential of the flattening filter free (FFF) mode of a
linear accelerator for intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for
patients with in-field recurrence of vertebral metastases.
Methods: An Elekta Synergy Linac with Agility™ head is used to simulate the treatment of ten patients with locally
recurrent spinal column metastases. Four plans were generated for each patient treating the vertebrae sparing the
spinal cord: Dual arc VMAT and nine field step and shoot IMRT each with and without flattening filter. Plan quality
was assessed considering target coverage and sparing of the spinal cord and normal tissue. All plans were verified
by a 2D-ionisation-chamber-array, peripheral doses were measured and compared to calculations. Delivery times
were measured and compared. The Wilcoxon test was used for statistical analysis with a significance level of 0.05.
Results: Target coverage, homogeneity index and conformity index were comparable for both flat and flattening
filter free beams. The volume of the spinal cord receiving the allowed maximum dose to keep the risk of radiation
myelopathy at 0 % was at the same time significantly reduced to below the clinically relevant 1 ccm using FFF
mode. In addition the mean dose deposited in the surrounding healthy tissue was significantly reduced in the FFF
mode. All four techniques showed equally good gamma scores for plan verification. FFF plans required considerably
more MU per fraction dose. Regardless of the large number of MU, out-of-field point dose was significantly lower for FFF
plans, with an average reduction of 33 % and mean delivery time was significantly reduced by 22 % using FFF beams.
When compared to IMRT FF, VMAT FFF offered even a reduction of 71 % in delivery time and 45 % in peripheral dose.
Conclusions: FFF plans showed a significant improvement in sparing of normal tissue and the spinal cord, keeping
target coverage and homogeneity comparable. In addition, delivery times were significantly reduced for FFF treatments,
minimizing intrafractional motion as well as strain for the patient. Shortest delivery times were achieved using VMAT FFF.
For radiotherapy of spinal column metastases VMAT FFF may therefore be considered the preferable treatment option
for the combination of Elekta Synergy Linacs and Oncentra® External Beam v4.5 treatment planning system.
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Background
The flattening filter in the treatment head of a linear ac-
celerator allows achieving a homogeneous dose profile
for photon beams. In the past this was necessary for 2D
radiation therapy planning and facilitated forward 3D ra-
diation therapy planning. The use of flattening filters im-
plies, however, also certain disadvantages: The flattening
filter reduces photon fluence, leading to lower dose rates
and prolonged beam-on times, and increases scatter
dose produced in the treatment head [1–3]. Through the
development of intensity modulated radiation therapy
(IMRT) and the associated inverse treatment planning, a
homogeneous beam profile is no longer necessary. The
latest development in the technology of linear accelera-
tors is therefore the opportunity to irradiate patients
without a flattening filter in the beam path to increase
dose rate and reduce beam-on times as well as out-of-
field doses [1]. The physical properties of flattening filter
free beams have been subject to a wide number of inves-
tigations during the last years [4–14]. Several treatment
planning studies have been published to assess the clin-
ical value of FFF beams for patient treatment, most of
them using Varian linear accelerators [15–23]. The flat-
tening filter free technique became commercially avail-
able for Elekta linear accelerators in 2013, therefore only
a few planning studies are available for Elekta up to
now, most of them conducted in the treatment planning
system Monaco for stereotactic treatments [24–27].
Only a few planning studies also consider the benefit of
a potential reduction in peripheral dose [2, 25].
Since patients with spinal metastases suffer from enor-
mous pain, a reduction in delivery time would mean less
emotional strain for the patients as well as reduced risk
for intrafractional motion [28]. A reduction in peripheral
dose leads in general to a reduction in normal tissue
complication probability. The purpose of the project
presented here was therefore to investigate the benefit of
flattening filter free beams in the re-irradiation of spinal
column metastases considering plan quality, total deliv-
ery time and peripheral dose.
Methods
Patients
CT data of ten patients with spinal column metastases
who had previously been treated with 3D-CRT were se-
lected from our treatment database. These data had pre-
viously been used for another study with identical
delineation of the planning target volume (PTV) and or-
gans at risk (OAR) and dose prescription [29]. The PTV
of the first course (pre-irradiation) consisted of the 1–5
thoracic vertebrae including the spinal cord. For this
study it was assumed that the patients have an in-field
recurrence and the whole vertebra region including the
spinal canal was pretreated with a dose of 10 × 3 Gy in
the first course. For the second course considered in this
planning study, the CTV consists of one to five whole
vertebrae including the vertebral body, the vertebral
arch, the transverse processes and the spinous process.
The spinal canal is excluded from the CTV and consid-
ered as organ at risk. The PTV is defined as CTV ex-
tended by a 3 mm margin in each direction excluding
the spinal canal from this expansion. Volumes of the
PTV ranged from 101 to 388 ccm, with a cranio-caudal
extension ranging from 4 to 11.5 cm. Prescription for
the second course is 6 × 4 Gy average dose to the PTV.
To avoid myelopathy the dose to the spinal cord was re-
stricted to 18 Gy due to the exposure in the first series.
The restriction to 18 Gy was calculated based on the
risk score model of Nieder et al. [30, 31] who found no
incidence of radiation myelopathy after a total biologic-
ally effective dose BED of 120 Gy2, if the interval be-
tween radiation courses was at least 6 months and the
BED of each course was not higher than 98 Gy2. The α/
β value for spinal cord was hereby assumed to be 2 Gy
[30, 31]. The biologically effective dose is defined as
BED = n ∙ d ∙ (1 + d/(α/β)) according to Fowler [32],
where n is the number of fractions, d the dose per frac-
tion and α and β the coefficients of the linear quadratic
cell model. Since the BED of the first course considered in
our study was 75 Gy2, the remaining maximum BED for
the second course was 45 Gy2 corresponding to 6 × 3 Gy to
assure a total maximum BED of 120 Gy2, i.e. a 0 % risk of
radiation myelopathy. Details about the calculation are de-
scribed in Groeger et al. [29].
Linear accelerator and treatment planning system
Treatment planning is performed with Oncentra® Exter-
nal Beam v4.5 (Nucletron, an Elekta Company) for a
Synergy linear accelerator with Agility™ head (Elekta AB,
Stockholm, Sweden) and six MV photons with flattening
filter (FF) or without (FFF). The FFF beams were
energy-matched to the FF beams as it is common for
Elekta accelerators [12, 13, 33]. The multi leaf collimator
consists of 80 leaf pairs of 5 mm width at isocenter. The
maximum nominal dose rate is 500 MU/min in FF
Mode and 1700 MU/min in FFF mode. Beam profiles,
depth doses and dose output were found to be stable for
4 MU and larger in both irradiation modes as also
reported by Akino [14]. Verification of the linac model
in Oncentra by collapsed cone dose calculations of per-
centage depth doses, profiles and output factors was
within specifications of Oncentra®, i.e. 3 % of calibration
dose in the dose plateau and 3 mm distance deviation to
correct dose value in sharp dose gradients, for both FF
and FFF. The accuracy of the collapsed cone dose calcu-
lation algorithm implemented in Oncentra has previ-
ously been reported to be at least as high for FFF beams
as for FF beams [34].
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Treatment planning
In total four treatment plans were created for each pa-
tient, using two different treatment techniques IMRT
and volumetric modulated arc therapy (VMAT) and two
different irradiation modes with and without flattening
filter. In the following the plans are referred to as IMRT
FF, IMRT FFF, VMAT FF and VMAT FFF. The IMRT
plans consist of nine equispaced beams, minimal seg-
ment size was 9 cm2, maximal number of segments
allowed was 70. Minimal number of monitor units per
segment is four due to the determined stability of the
beam for 4 MU and higher. The VMAT plans consist of
two full rotations with gantry spacing between two con-
trol points of 4°. Collimator angles ranged from 0 to 45°
for both techniques. Identical dose volume objectives
(DVO) and weights were used for optimization of all
plans (Table 1). Suitable DVO and weights were deter-
mined creating plans in FF mode which met the goals
and then transferred to the FFF plans. All plans were ac-
cepted for treatment by a specialized radiation
oncologist.
Dosimetry
For verification all 40 plans were transferred to a CT scan
of the MatriXX Evolution™ 2D-ionisationchamber-array
(IBA Dosimetry, Schwarzenbruck, Germany) set up in be-
tween slabs of a RW3 phantom (PTW, Freiburg,
Germany) for measurement in a coronal plane [35, 36].
The 2D-ionisationchamber-array MatriXX Evolution™
consists of 1020 vented pixel ionisationchambers arranged
in a square of 24.4 cm × 24.4 cm with a center-to-center
distance of 0.76 cm, the chamber size is 0.45 cm diameter
and 0.5 cm height, the active volume is 0.08 cm3, and
RW3 is used as backscatter material. RW3 consists of
white polystyrene and is dosimetrically water-equivalent
for photons in the range of 60Co to 25 MV. The isocenter
was placed such that the measurement plane intersected
both the PTV and the spinal cord in order to verify the
dose to the PTV and the dose to the organ at risk at the
same time. This is possible considering the diameter of
the spinal cord of around 1.5 cm, the chamber distance of
0.76 cm and the active chamber volume of 0.08 cm3. It
should be mentioned, however, that the measurement of
very steep gradients between PTV and spinal cord is lim-
ited by the chamber distance. The dose in the measure-
ment plane was calculated with a dose grid resolution of
0.15 cm, all other parameters were kept identical to the
patient plan. The plans were then delivered to the phan-
tom. Measurements were corrected for angular dependen-
cies and couch attenuation in the steering and evaluation
software OmniPro I’mRT v.1.7a (IBA Dosimetry, Schwar-
zenbruck, Germany). In addition a point dose measure-
ment was performed in the same coronal plane but 31 cm
cranial of the isocenter using a 0.3 ccm PTW ionization
chamber to assess peripheral dose. The dose at the point
of measurement was calculated in Oncentra on the CT
scan of the phantom. The complete measurement setup is
shown in Fig. 1.
Efficiency
Delivery times were measured from first beam on to last
beam off to assess the achievable reduction in delivery
time. In addition the number of required monitor units
(MU) per Gray was compared.
Evaluation
Plan quality was assessed by analysis of the dose vol-
ume histogram (DVH) with respect to target cover-
age, dose homogeneity and conformity, dose to the
spinal cord and normal tissue. Target coverage was
represented by the volume of the PTV covered by
95 % of the prescription dose (V95%). The homogen-
eity index was defined as HI := (D1% - D99%)/D50%,
the conformity index according to Paddick et al. [37]
as CI := V95%
2 /(TV ⋅ PIV). Here TV means the vol-
ume of the PTV, PIV the total volume covered by
95 % of the prescription dose. To assess the sparing
of the spinal cord as described in the treatment goals,
the volume V75% covered by 75 % of the prescription
dose i.e. 18 Gy was recorded. The value of 18 Gy was
calculated as residual tolerance dose due to the ex-
posure in the first series. According to ICRU report
50 “a significant tissue volume must be irradiated for
the dose level to be reported as maximum” [38].
ICRU report 80 suggests that D2% may be an appro-
priate value if the whole structure is delineated [39],
which corresponds to a volume of about 1 ccm which
is also commonly used in the literature [40]. The me-
dian dose D50% of the normal tissue, which is defined
as the patient body excluding the PTV, is listed as a
measure of low dose in the periphery.
For evaluation of plan verifications gamma indices as
defined by Low et al. [41] were calculated with a dose
Table 1 Dose Volume Objectives (DVO)
Organ Type DVO relative
weight
PTV target uniform dose 24.0 Gy 7000
minimum dose 23.5 Gy 7000
maximum dose 24.5 Gy 7000
spinal canal organ at risk maximum dose 18.0 Gy 750
spinal cord organ at risk maximum dose 16.0 Gy 1000
normal
tissue
organ at risk maximum dose 24.5 Gy 5000
surrounding dose fall off from
24.0 to 4.8 Gy in 5.0 cm
5000
Identical dose volume objectives (DVO) and weights were used for optimization
of all plans
Dobler et al. Radiation Oncology  (2016) 11:33 Page 3 of 9
tolerance of 3 % of the maximum dose and 3 mm dis-
tance to agreement. Dose calculations are considered ac-
ceptable if at least 95 % of the pixels with a dose value
of ≥ 10 % of the maximum dose have a gamma value ≤ 1
as recommended by the AAPM TG119 [42, 43]. Ionch-
amber point dose measurements and corresponding cal-
culations 31 cm cranial of the isocenter were compared
for the two irradiation modes to assess peripheral dose.
The Wilcoxon test implemented in IBM SPSS® Statis-
tics 23.0 (IBM Corporation) was used for statistical ana-
lysis with a significance level of 0.05 of a) the FF mode
versus the FFF mode separated by the planning tech-
niques IMRT and VMAT and b) IMRT versus VMAT
separated by the irradiation mode FF and FFF. For the
assessment of peripheral dose and delivery time, the
Wilcoxon test was also performed for all plans in FF
mode versus FFF mode.
Results
Since the main subject of the study was the compari-
son of the two irradiation modes FF and FFF, details
about statistical significance are listed in the tables
for these Wilcoxon tests. Differences between IMRT
and VMAT are mentioned in the text but not listed
in detail in the tables for the sake of clarity.
Plan quality
Analysis of the dose volume parameters listed in detail
in Table 2 shows slightly higher plan quality for both
IMRT and VMAT, if flattening filter free beams were
used: the volume of the spinal cord receiving the allowed
maximum dose as well as the dose to the normal tissue
could be significantly reduced keeping target coverage,
homogeneity and conformity at the same level. The vol-
ume of the spinal cord receiving 18 Gy was kept well
below the clinically relevant volume of 1 ccm in all cases
if FFF mode was used but exceeded 1 ccm in 50 % of the
cases for FF mode, with a maximum volume of 2.2 ccm.
Comparison of VMAT versus IMRT also showed signifi-
cant differences in target coverage and homogeneity as
well as sparing of the spinal cord and normal tissue. Best
target coverage and homogeneity were achieved with
VMAT FFF, whereas lowest doses to the spinal cord and
normal tissue were achieved with IMRT FFF. A compari-
son of dose distributions and dose volume histograms is
shown in Figs. 2 and 3 for a typical case.
Dosimetry
All 40 plans passed the gamma evaluation. Passing rates
were similar for both techniques and showed no signifi-
cant difference between FF and FFF or IMRT and
VMAT. Details are listed in Table 3.
Fig. 1 Measurement setup at the linac. The 2D-ionisationchamber-array MatriXX EvolutionTM was set up between slabs of RW3 and centered at the
isocenter of the linac. The setup was extended cranially by additional slabs of RW3 of the same height with a 0.3 ccm ionisation chamber positioned
31 cm cranially of the isocenter
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Out-of-field point doses measured at 31 cm from the
isocenter were significantly reduced for FFF as compared
to FF. Averaged over all plans a dose reduction of
33.2 % ± 5.4 % of the local dose was achieved. The lowest
out-of-field point dose was found for VMAT FFF, which
was significantly lower than for IMRT FFF (p < 0.01).
Calculation of the peripheral dose at the point of meas-
urement in the phantom in Oncentra showed no signifi-
cant differences between the FF and FFF. Comparison of
calculated versus measured peripheral doses showed a
mean local dose deviation of - 33.6 % ± 16.6 % for flat
beams and −2.0 % ± 29.4 % for FFF beams. Details are
listed in Table 3.
Efficiency
FFF Plans required significantly more MU per fraction
dose for both IMRT and VMAT, whereas no significant
difference could be found between IMRT and VMAT in
both irradiation modes. Details are listed in Table 3.
Table 2 Comparison of plan quality
IMRT VMAT
Parameter FF FFF p FF FFF p
PTV V95% (%) 86.4 ± 1.7 88.4 ± 1.7 <0.01 91.0 ± 1.5 91.7 ± 1.3 0.14
HI 0.27 ± 0.02 0.26 ± 0.02 0.06 0.23 ± 0.02 0.23 ± 0.02 0.96
CI 0.65 ± 0.04 0.66 ± 0.04 0.17 0.65 ± 0.04 0.66 ± 0.04 0.51
Spinal Cord D50% 15.9 ± 0.6 15.1 ± 0.5 <0.01 15.6 ± 0.3 15.0 ± 0.4 0.01
V75% (ccm) 0.9 ± 0.3 0.5 ± 0.1 <0.01 1.0 ± 0.5 0.7 ± 0.2 0.01
Normal Tissue D50% 0.8 ± 0.4 0.6 ± 0.4 <0.01 1.1 ± 0.7 0.8 ± 0.6 <0.01
Mean values and standard deviation of the dose volume parameters for the four different planning techniques averaged over all patients. Dose values are given
in Gy. P-values for comparison of FF and FFF are calculated separately for IMRT and VMAT. Bold values indicate significantly superior values
Fig. 2 Comparison of dose distributions. Comparison of dose distributions in one transversal slice for a representative case. Top IMRT, bottom VMAT, left
FF, right FFF
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Delivery time was significantly reduced for FFF beams
in both treatment techniques. Averaged over all patients
the delivery time was reduced from 557 to 438 s for
IMRT and 216 s to 163 s for VMAT, which corresponds
to a reduction of 21 % ± 4 % for IMRT and 24 % ± 5 %
for VMAT. The lowest delivery time was found for
VMAT FFF, which was significantly lower than for
IMRT FFF (p < 0.01). Details about delivery times are
listed in Table 3.
Discussion
The aim of this study was to investigate the potential of
the flattening filter free (FFF) mode of a linear acceler-
ator for intensity modulated radiation therapy (IMRT)
and volumetric modulated arc therapy (VMAT) for pa-
tients with in-field recurrence of vertebral metastases.
The data show significant advantages for FFF beams as
compared to FF beams in terms of plan quality as well
as delivery time and peripheral dose: FFF offered a sig-
nificant improvement in the sparing of normal tissue
and the spinal cord, which could be of importance, min-
imizing the risk of radiation myelopathy, keeping target
coverage and homogeneity at the same level. According
to the literature [31], the risk for radiation myelopathy is
0 % if the BED of each series is ≤ 98 Gy2, the interval be-
tween the series is at least 6 months, and the total BED
of all series is ≤ 120 Gy2. The risk increases to 3 % for an
upper limit of the total BED of 135.5 Gy2. In the sce-
nario presented here this means that the dose to the
spinal cord has to be restricted to 18 Gy to assure a 0 %
risk of myelopathy. The volume of the spinal cord re-
ceiving 18 Gy was kept well below the clinically relevant
volume of 1 ccm in all cases if FFF mode was used, but
exceeded 1 ccm in 50 % of the cases, when FF mode was
used. The reason for the better sparing of the spinal cord
may be found in the shape of the dose profiles for beams
Fig. 3 Comparison of dose volume histograms. Comparison of dose volume histograms for the case of Fig. 2
Table 3 Comparison of plan delivery and evaluation of dosimetry
IMRT VMAT
Parameter FF FFF p FF FFF p
Delivery time (s) 557 ± 41 438 ± 23 <0.01 216 ± 15 163 ± 5 <0.01
Monitor units per Gy 381 ± 25 448 ± 43 <0.01 391 ± 29 429 ± 37 0.02
Measured peripheral dose (mGy) 8.6 ± 1.4 5.8 ± 1.2 <0.01 7.0 ± 1.0 4.8 ± 1.0 <0.01
Calculated peripheral dose (mGy) 4.7 ± 1.3 4.6 ± 1.5 0.51 5.7 ± 1.4 5.6 ± 1.4 0.24
Passing rate of γ (%) 97.6 ± 1.1 97.4 ± 1.2 0.51 98.1 ± 1.1 97.9 ± 1.0 0.37
Mean values and standard deviation of delivery time, monitor units, measured and calculated peripheral doses and result of the gamma evaluation for the four
different planning techniques averaged over all ten patients. P-values for comparison of FF and FFF are calculated separately for IMRT and VMAT. Bold values indicate
significantly superior values
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with the central part blocked: For the peak formed pro-
file of the FFF beams the gradient towards the blocked
center is slightly steeper than of FF beams. The lower
dose to the normal tissue in the periphery can be ex-
plained by reduced head scatter if the flattening filter is
removed. In spite of increased MU in the FFF mode, de-
livery time and peripheral dose exposure are reduced,
which means less strain for the patient and possibly re-
duced risk of normal tissue complications. When com-
pared to IMRT FF, VMAT FFF offered a reduction of
71 % in delivery time and 45 % peripheral dose. Accord-
ing to Ma et al. [28] the critical time to keep target mo-
tion within 1 mm of translation or 1° of rotational
deviation is 5.9 min (354 s) when patients are immobi-
lized in a vacuum cushion. This was achieved in all cases
of our study for VMAT only. In summary VMAT FFF
may therefore be considered the preferable treatment
option for radiotherapy of spinal column metastases
which the combination of Elekta Synergy linacs with
Agility™ head and the treatment planning system Oncen-
tra® External Beam v4.5.
Concerning plan quality there is a broad variety in the
studies published up to now: For small targets with low
modulation, as they are common in stereotactic treat-
ments, plan quality was mostly found to be comparable
[19, 26]. For larger targets, one group reported similar
target coverage at significantly reduced doses to organs
at risk for FFF beams [15, 21] which is in concordance
with our findings. Other studies found superior plan
quality for flat beams [20, 44, 45]. The only planning
study dealing with irradiation of vertebrae with FFF
beams has to our knowledge been published by Ong et
al. for RapidArc plans created in the Eclipse planning
system for Varian linear accelerators [23]. In their study
different fractionation schemes of single doses ranging
from 9 to 16 Gy were used and plans were normalized
with respect to acceptable dose to the spinal cord. Ong
et al. found slightly increased target dose for FFF as
compared to FF, which is in concordance with the
results of our study presented here. However, photon
energies used in their study differed between FF (6
MV) and FFF (10 MV), which might bias the results,
whereas we used the same energy for both irradiation
modes in our study. Validation of the dose calcula-
tion by measurements in the study of Ong et al.
showed good agreement for a region receiving more
than 20 % of the prescription dose, evaluation of per-
ipheral low dose was not performed. Reduction in
delivery time was more pronounced in the study of
Ong et al., with a higher mean for FF (402 s vs
216 s) and a comparable mean for FFF (168 s versus
163 s), since the benefit of higher dose rates is more
pronounced for higher fraction doses as they are
used in the study of Ong.
Reduction in out-of-field dose has been reported pre-
viously in the context of Monte Carlo simulations of FFF
beams for both Elekta [13] and Varian [46]. The authors
emphasize, however, that a reduction of peripheral dose
in patient treatments “may not always be achievable”
due to dependence on many parameters [46]. Most of
the planning studies published up to now did not take
peripheral dose measurements into account. Spruijt et
al. [20] performed a planning study for breast cancer
and created one phantom case for out-of-field dose mea-
surements 0.3 cm to 3.1 cm from the field edge. They
found an average reduction in out-of-field dose of 10 %.
Comparison to dose calculations in this region showed,
however, an underestimation by the treatment planning
system Eclipse of 26 % to 85 % as compared to measure-
ments. Absolute dose values are not reported. Because
of the uncertainties in the dose calculation the authors
abandoned evaluation of dose volume parameters of the
contralateral breast in their planning study. Kragl et al.
[2] measured peripheral dose for four sample cases, one
7-field phantom plan, one lung SBRT, one prostate
IMRT and one head and neck IMRT case and found a
substantial local dose reduction at around 20 cm from
the field edge. Because only one case per technique was
considered, no conclusion with statistical significance
could be drawn. The results of our study evaluated for a
larger number of cases support their findings with statis-
tical evidence. As Kragl et al. pointed out, peripheral
doses are difficult to calculate correctly with a high ac-
curacy, and should therefore be determined by measure-
ments or Monte Carlo simulations. Therefore they did
not compare the peripheral dose measurements with
calculations. Comparison of calculated versus measured
peripheral doses in our study showed significantly higher
agreement between calculated and measured peripheral
doses for FFF beams than for FF beams. The calculation
in Oncentra did not reveal the actual reduction of per-
ipheral dose which is possible to achieve by the use of
FFF due to a systematic underestimation of the periph-
eral dose for FF beams, which was not observed for FFF
beams. Thus, the advantage of FFF determined in the
calculated DVH of the normal tissue is even underesti-
mated by the dose calculation in Oncentra.
Conclusions
For the combination of an Elekta Synergy linac with Agil-
ity™ head and the treatment planning system Oncentra®
External Beam v4.5 the use of flattening filter free beams
in re-irradiation of spinal column metastases allows better
sparing of the spinal cord, minimizing the risk of radiation
myelopathy, without compromising target coverage and
homogeneity for both IMRT and VMAT. Delivery time is
significantly lower as compared to flat beams, which may
reduce intrafractional movement and emotional strain to
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the patient. When compared to IMRT FF, VMAT FFF
offered a reduction of 71 % in delivery time and 45 % in
peripheral dose. For radiotherapy of spinal column metas-
tases VMAT FFF may therefore be considered the prefera-
ble treatment option for the combination of Elekta
Synergy linacs with Agility™ head and the treatment plan-
ning system Oncentra® External Beam v4.5.
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